Search - tctmd.com

Displaying 701 - 720 of 9980

Sort: Relevancy | Date

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Daily News

AHA Tackles Need for Increased CV Prevention in Emerging Adults

Yael L. Maxwell

April 09, 2025

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

L.A. McKeown

April 07, 2025

News Daily News

CMS Releases Proposed Decision Memo for Tricuspid TEER

L.A. McKeown

April 04, 2025

Podcast Heart Valve Matters

Technology's Role in Treating Severe AS with Sammy Elmariah and David Playford

April 04, 2025

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News EHRA 2025

Pulsed-Field Ablation Equals, and May Top, Cryoablation for Paroxysmal AF

Todd Neale

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

Advertisement

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

AHA Tackles Need for Increased CV Prevention in Emerging Adults

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

CMS Releases Proposed Decision Memo for Tricuspid TEER

Technology's Role in Treating Severe AS with Sammy Elmariah and David Playford

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Pulsed-Field Ablation Equals, and May Top, Cryoablation for Paroxysmal AF

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

WARRIOR: No Clear Answers on How to Best Treat INOCA

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content